Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
ACON vs NVCR vs ISRG vs MDT vs SYK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
ACON vs NVCR vs ISRG vs MDT vs SYK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices |
| Market Cap | $3M | $1.92B | $161.07B | $99.94B | $112.69B |
| Revenue (TTM) | $75.73B | $674M | $10.58B | $35.48B | $25.12B |
| Net Income (TTM) | $-7.23T | $-173M | $2.98B | $4.61B | $3.25B |
| Gross Margin | 9.0% | 75.2% | 66.3% | 61.9% | 63.5% |
| Operating Margin | -93.1% | -27.2% | 30.5% | 17.9% | 22.4% |
| Forward P/E | — | — | 43.8x | 14.1x | 19.6x |
| Total Debt | $0.00 | $290M | $303M | $28.52B | $14.86B |
| Cash & Equiv. | $12.02T | $103M | $3.37B | $2.22B | $4.01B |
ACON vs NVCR vs ISRG vs MDT vs SYK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Apr 22 | May 26 | Return |
|---|---|---|---|
| Aclarion, Inc. (ACON) | 100 | 0.0 | -100.0% |
| NovoCure Limited (NVCR) | 100 | 22.0 | -78.0% |
| Intuitive Surgical,… (ISRG) | 100 | 189.5 | +89.5% |
| Medtronic plc (MDT) | 100 | 74.7 | -25.3% |
| Stryker Corporation (SYK) | 100 | 122.0 | +22.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ACON vs NVCR vs ISRG vs MDT vs SYK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
ACON is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.
- Rev growth 1000K%, EPS growth 99.8%, 3Y rev CAGR 106.8%
- Beta 0.98, yield 100.0%, current ratio 14.81x
- 1000K% revenue growth vs MDT's 3.6%
- 100.0% yield, 1-year raise streak, vs MDT's 3.6%, (2 stocks pay no dividend)
NVCR ranks third and is worth considering specifically for momentum.
- +1.1% vs ACON's -56.2%
ISRG is the clearest fit if your priority is long-term compounding.
- 5.5% 10Y total return vs SYK's 187.1%
- 28.2% margin vs ACON's -95.5%
MDT carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Lower volatility, beta 0.47, Low D/E 59.1%, current ratio 1.85x
- Lower P/E (14.1x vs 43.8x)
- Beta 0.47 vs NVCR's 2.20, lower leverage
SYK is the clearest fit if your priority is valuation efficiency.
- PEG 1.32 vs MDT's 36.00
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 1000K% revenue growth vs MDT's 3.6% | |
| Value | Lower P/E (14.1x vs 43.8x) | |
| Quality / Margins | 28.2% margin vs ACON's -95.5% | |
| Stability / Safety | Beta 0.47 vs NVCR's 2.20, lower leverage | |
| Dividends | 100.0% yield, 1-year raise streak, vs MDT's 3.6%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +1.1% vs ACON's -56.2% | |
| Efficiency (ROA) | 175.8% ROA vs ACON's -211.6%, ROIC 6.0% vs -12.9% |
ACON vs NVCR vs ISRG vs MDT vs SYK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
ACON vs NVCR vs ISRG vs MDT vs SYK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
MDT leads 1 • ACON leads 0 • NVCR leads 0 • SYK leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACON is the larger business by revenue, generating $75.7B annually — 112.3x NVCR's $674M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ACON's -95.5%. On growth, ACON holds the edge at +999999.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $75.7B | $674M | $10.6B | $35.5B | $25.1B |
| EBITDAEarnings before interest/tax | -$7.05T | -$165M | $3.8B | $9.4B | $6.3B |
| Net IncomeAfter-tax profit | -$7.23T | -$173M | $3.0B | $4.6B | $3.2B |
| Free Cash FlowCash after capex | -$7.16T | -$48M | $2.8B | $5.4B | $4.3B |
| Gross MarginGross profit ÷ Revenue | +9.0% | +75.2% | +66.3% | +61.9% | +63.5% |
| Operating MarginEBIT ÷ Revenue | -93.1% | -27.2% | +30.5% | +17.9% | +22.4% |
| Net MarginNet income ÷ Revenue | -95.5% | -25.7% | +28.2% | +13.0% | +12.9% |
| FCF MarginFCF ÷ Revenue | -94.6% | -7.1% | +26.8% | +15.2% | +17.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +999999.0% | +12.3% | +23.0% | +8.8% | +11.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +99.9% | -100.0% | +18.8% | -11.9% | +56.0% |
Valuation Metrics
MDT leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.36x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3M | $1.9B | $161.1B | $99.9B | $112.7B |
| Enterprise ValueMkt cap + debt − cash | -$12.02T | $2.1B | $158.0B | $126.2B | $123.5B |
| Trailing P/EPrice ÷ TTM EPS | -0.23x | -13.80x | 57.62x | 21.60x | 35.03x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 43.84x | 14.13x | 19.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 2.65x | 36.00x | 2.36x |
| EV / EBITDAEnterprise value multiple | — | — | 43.62x | 14.32x | 20.31x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | 2.92x | 16.00x | 2.98x | 4.49x |
| Price / BookPrice ÷ Book value/share | 0.00x | 5.51x | 9.17x | 2.08x | 5.02x |
| Price / FCFMarket cap ÷ FCF | — | — | 64.67x | 19.28x | 26.31x |
Profitability & Efficiency
ISRG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-2 for ACON. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs ACON's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.3% | -50.8% | +16.9% | +9.4% | +15.0% |
| ROA (TTM)Return on assets | -2.1% | -16.5% | +14.8% | +175.8% | +6.9% |
| ROICReturn on invested capital | -12.9% | -16.4% | +15.0% | +6.0% | +11.4% |
| ROCEReturn on capital employed | -109.9% | -28.9% | +16.5% | +7.5% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 6 | 6 | 6 |
| Debt / EquityFinancial leverage | — | 0.85x | 0.02x | 0.59x | 0.66x |
| Net DebtTotal debt minus cash | -$12.02T | $187M | -$3.1B | $26.3B | $10.8B |
| Cash & Equiv.Liquid assets | $12.02T | $103M | $3.4B | $2.2B | $4.0B |
| Total DebtShort + long-term debt | $0 | $290M | $303M | $28.5B | $14.9B |
| Interest CoverageEBIT ÷ Interest expense | — | -96.80x | — | 9.08x | 6.72x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $0 for ACON. Over the past 12 months, NVCR leads with a +1.1% total return vs ACON's -56.2%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs ACON's -96.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -36.5% | +28.3% | -19.3% | -18.1% | -15.2% |
| 1-Year ReturnPast 12 months | -56.2% | +1.1% | -15.4% | -2.8% | -22.5% |
| 3-Year ReturnCumulative with dividends | -100.0% | -75.7% | +49.6% | -4.2% | +5.5% |
| 5-Year ReturnCumulative with dividends | -100.0% | -91.3% | +58.7% | -27.7% | +21.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | +30.3% | +554.2% | +26.5% | +187.1% |
| CAGR (3Y)Annualised 3-year return | -96.9% | -37.6% | +14.4% | -1.4% | +1.8% |
Risk & Volatility
Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs ACON's 26.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 2.20x | 1.02x | 0.47x | 0.55x |
| 52-Week HighHighest price in past year | $12.03 | $20.06 | $603.88 | $106.33 | $404.87 |
| 52-Week LowLowest price in past year | $2.34 | $9.82 | $427.84 | $77.16 | $289.91 |
| % of 52W HighCurrent price vs 52-week peak | +26.3% | +83.9% | +75.1% | +73.3% | +72.7% |
| RSI (14)Momentum oscillator 0–100 | 48.3 | 69.8 | 42.4 | 27.3 | 24.3 |
| Avg Volume (50D)Average daily shares traded | 103K | 1.5M | 1.8M | 7.8M | 2.1M |
Analyst Outlook
Evenly matched — ACON and MDT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: NVCR as "Buy", ISRG as "Buy", MDT as "Buy", SYK as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 37.2% for SYK (target: $404). For income investors, ACON offers the higher dividend yield at 100.00% vs SYK's 1.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $33.50 | $622.60 | $109.50 | $403.69 |
| # AnalystsCovering analysts | — | 15 | 55 | 49 | 50 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — | — | +3.6% | +1.1% |
| Dividend StreakConsecutive years of raises | 1 | — | — | 36 | 34 |
| Dividend / ShareAnnual DPS | $10196.68 | — | — | $2.78 | $3.36 |
| Buyback YieldShare repurchases ÷ mkt cap | +45.0% | 0.0% | +1.4% | +3.2% | 0.0% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDT leads in 1 (Valuation Metrics). 2 tied.
ACON vs NVCR vs ISRG vs MDT vs SYK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is ACON or NVCR or ISRG or MDT or SYK a better buy right now?
For growth investors, Aclarion, Inc.
(ACON) is the stronger pick with 999999% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — ACON or NVCR or ISRG or MDT or SYK?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — ACON or NVCR or ISRG or MDT or SYK?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -100. 0% for Aclarion, Inc. (ACON). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus ACON's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — ACON or NVCR or ISRG or MDT or SYK?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — ACON or NVCR or ISRG or MDT or SYK?
By revenue growth (latest reported year), Aclarion, Inc.
(ACON) is pulling ahead at 999999% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Aclarion, Inc. grew EPS 99. 8% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, ACON leads at 106. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — ACON or NVCR or ISRG or MDT or SYK?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -95. 5% for Aclarion, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -93. 1% for ACON. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is ACON or NVCR or ISRG or MDT or SYK more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — ACON or NVCR or ISRG or MDT or SYK?
In this comparison, ACON (100.
0% yield), MDT (3. 6% yield), SYK (1. 1% yield) pay a dividend. NVCR, ISRG do not pay a meaningful dividend and should not be held primarily for income.
09Is ACON or NVCR or ISRG or MDT or SYK better for a retirement portfolio?
For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
55), 1. 1% yield, +187. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between ACON and NVCR and ISRG and MDT and SYK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ACON is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock; SYK is a mid-cap quality compounder stock. ACON, MDT, SYK pay a dividend while NVCR, ISRG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.